Companies Embrace Autophagy Inhibitors


April 29, 2011

Journal of the National Cancer Institute

Ravi Amaravadi, MD, an assistant professor in the division of Hematology/Oncology, is quoted in a Journal of the National Cancer Institute article about the growing number of clinical trials for autophagy inhibitors in cancer treatment. Although autophagy, the process of "self-eating" within cells, has been controversial in cancer since it was first linked to the disease in 1999, since it can either suppress or promote tumors growth, consensus is emerging now that autophagy suppresses growth early in tumor development but promotes growth later. "The field is now fully on board with that," Amaravadi says. "Once tumors are established, especially in the tumor microenvironment, and especially in the context of cancer therapy, autophagy is a tumor-promoting mechanism." Read More